| Anandhi Baleswaren, MD | |
|
481 Gold Star Hwy, Suite 100, Groton, CT 06340-6702 | |
| (860) 446-8858 | |
| (860) 405-2140 |
| Full Name | Anandhi Baleswaren |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | 481 Gold Star Hwy, Groton, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346246444 | NPI | - | NPPES |
| 001386045 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 038604 (Connecticut) | Primary |
| 208000000X | Pediatrics | 038604 (Connecticut) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lawrence & Memorial Hospital | New london, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Health Center Inc | 0547169138 | 51 |
News Archive
Massachusetts Health Quality Partners announced today that despite improvement, there are significant differences in the quality of care delivered by medical groups in Massachusetts, according to its annual Quality Insights: Clinical Quality in Primary Care report.
Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial.
The New York State Department of Health (DOH) has granted Roswell Park Cancer Institute (RPCI) approval to begin genomic testing of cancer patients using its OmniSeq TargetTM advanced molecular diagnostic laboratory test.
A new study, conducted by the not-for-profit research organisation RAND Europe, has found that measures and tools used to assess quality of life are not being used widely in the treatment and care of patients with cancer, despite being used more widely in clinical trials.
The rates of men dying from malignant melanoma - the deadliest form of skin cancer - have doubled in the last 30 years, according to the latest Cancer Research UK figures published today.
› Verified 9 days ago
| Entity Name | Community Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952591851 PECOS PAC ID: 0547169138 Enrollment ID: O20040102000412 |
News Archive
Massachusetts Health Quality Partners announced today that despite improvement, there are significant differences in the quality of care delivered by medical groups in Massachusetts, according to its annual Quality Insights: Clinical Quality in Primary Care report.
Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial.
The New York State Department of Health (DOH) has granted Roswell Park Cancer Institute (RPCI) approval to begin genomic testing of cancer patients using its OmniSeq TargetTM advanced molecular diagnostic laboratory test.
A new study, conducted by the not-for-profit research organisation RAND Europe, has found that measures and tools used to assess quality of life are not being used widely in the treatment and care of patients with cancer, despite being used more widely in clinical trials.
The rates of men dying from malignant melanoma - the deadliest form of skin cancer - have doubled in the last 30 years, according to the latest Cancer Research UK figures published today.
› Verified 9 days ago
| Entity Name | Ipc Hospitalists Of New England Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821401761 PECOS PAC ID: 7618051442 Enrollment ID: O20091221000423 |
News Archive
Massachusetts Health Quality Partners announced today that despite improvement, there are significant differences in the quality of care delivered by medical groups in Massachusetts, according to its annual Quality Insights: Clinical Quality in Primary Care report.
Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial.
The New York State Department of Health (DOH) has granted Roswell Park Cancer Institute (RPCI) approval to begin genomic testing of cancer patients using its OmniSeq TargetTM advanced molecular diagnostic laboratory test.
A new study, conducted by the not-for-profit research organisation RAND Europe, has found that measures and tools used to assess quality of life are not being used widely in the treatment and care of patients with cancer, despite being used more widely in clinical trials.
The rates of men dying from malignant melanoma - the deadliest form of skin cancer - have doubled in the last 30 years, according to the latest Cancer Research UK figures published today.
› Verified 9 days ago
| Entity Name | Hospital Medicine Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093758781 PECOS PAC ID: 9234156985 Enrollment ID: O20170802002619 |
News Archive
Massachusetts Health Quality Partners announced today that despite improvement, there are significant differences in the quality of care delivered by medical groups in Massachusetts, according to its annual Quality Insights: Clinical Quality in Primary Care report.
Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial.
The New York State Department of Health (DOH) has granted Roswell Park Cancer Institute (RPCI) approval to begin genomic testing of cancer patients using its OmniSeq TargetTM advanced molecular diagnostic laboratory test.
A new study, conducted by the not-for-profit research organisation RAND Europe, has found that measures and tools used to assess quality of life are not being used widely in the treatment and care of patients with cancer, despite being used more widely in clinical trials.
The rates of men dying from malignant melanoma - the deadliest form of skin cancer - have doubled in the last 30 years, according to the latest Cancer Research UK figures published today.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anandhi Baleswaren, MD 481 Gold Star Hwy, Suite 100, Groton, CT 06340-6702 Ph: (860) 446-8858 | Anandhi Baleswaren, MD 481 Gold Star Hwy, Suite 100, Groton, CT 06340-6702 Ph: (860) 446-8858 |
News Archive
Massachusetts Health Quality Partners announced today that despite improvement, there are significant differences in the quality of care delivered by medical groups in Massachusetts, according to its annual Quality Insights: Clinical Quality in Primary Care report.
Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial.
The New York State Department of Health (DOH) has granted Roswell Park Cancer Institute (RPCI) approval to begin genomic testing of cancer patients using its OmniSeq TargetTM advanced molecular diagnostic laboratory test.
A new study, conducted by the not-for-profit research organisation RAND Europe, has found that measures and tools used to assess quality of life are not being used widely in the treatment and care of patients with cancer, despite being used more widely in clinical trials.
The rates of men dying from malignant melanoma - the deadliest form of skin cancer - have doubled in the last 30 years, according to the latest Cancer Research UK figures published today.
› Verified 9 days ago
Ann E Taylor, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: Pfizer, Eastern Point Road, Groton, CT 06340 Phone: 860-715-6348 | |
Dr. John William Lindsay, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 85 Poheganut Dr, Groton, CT 06340 Phone: 860-448-6303 Fax: 860-448-9678 | |
Dr. Joseph Onofrio Lopreiato Jr., M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Wahoo Ave, Groton, CT 06349 Phone: 860-694-4123 | |
C Wallace Andrias, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 235 Lestertown Rd, Groton, CT 06340 Phone: 860-822-3547 | |
Fred Yeo, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: Nhcne Groton, Groton, CT 06340 Phone: 860-694-6481 | |
Nimesh K Patel, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 404 Thames St, Suite 2, Groton, CT 06340 Phone: 860-445-0494 Fax: 860-445-4079 |